Anti-mIL-13-mIgG1
-
Cat.code:
mil13-mab9-02
- Documents
ABOUT
Recombinant fully mouse IL-13 antibody
InvivoGen provides a recombinant fully mouse anti-mouse IL-13 monoclonal antibody (mAb) that was previously extracted from hybridoma. It is now expressed and produced in Chinese hamster ovary (CHO) cells, ensuring reliability and lot-to-lot reproducibility. Thereby, common hybridoma-related drawbacks such as the generation of non-relevant mAbs containing aberrant light chains are avoided [1].
The sequence of Anti-mIL-13-mIgG1 is 100% murine (constant and variable regions), as the original clone (clone 8H8) was raised in mice using a proprietary method. This feature allows for reduced immunogenicity and risks of fatal hypersensitivity reactions upon repeated mAb injections into mice [2-4].
InvivoGen provides this antibody in two grades:
- In vitro use: Anti-mIL-13-mIgG1
- In vivo use: Anti-mIL-13-mIgG1 InvivoFit™
All InvivoFit™ products are handled in a clean room, filter-sterilized, and tested for bacterial contaminants. Additionally, this grade guarantees low levels of endotoxins (<1 EU/ml). The buffer formulation is specifically adapted for in vivo studies.
Key features:
- Potent and specific neutralizing activity against mIL-13
- Sequence is 100% murine
- Murine IgG1 isotype (constant region)
- Free from non-relevant mAbs found in hybridoma-based productions
- Produced in animal-free facilities and defined media
- Low aggregation < 5%
- InvivoFit™ grade is available
Anti-mIL-13-mIgG1 is designed to efficiently neutralize the biological activity of mIL-13. Interleukin (IL-)13 is a multifunctional cytokine that plays an important role in the regulation of inflammation and immune responses [5,6].
References:
1. Bradbury, A. et al., 2018. When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. mAbs, 10(4), 539–546.
2. Mall C. et al., 2016. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogenic hypersensitivity reactions in a murine model of breast cancer. Onco Immunol. 5(2):e1075114.
3. Murphy, J.T. et al., 2014. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood. 123(14):2172-2180.
4. Belmar N.A. et al., 2017. Murinization and H chain isotype matching of Anti-GITR antibody DTA-1 reduces immunogenicity-mediated anaphylaxis in C57BL/6 mice. J Immunol. 198:4502-4512.
5. Kasaian M.T. et al., 2013. An IL-4/IL-13 dual antagonist reduces lung inflammation, airway hyperresponsiveness, and IgE production in mice. Am J Respir Cell Mol Biol.49(1):37-46.
6. David M. et al., 2003. Functional characterization of IL-13 receptor a2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression. Oncogene 22, 3386-94.
All products are for research use only, and not for human or veterinary use.
InvivoFit™
InvivoFit™ is a high-quality standard specifically adapted for in vivo studies.
InvivoFit™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and a TLR2 and TLR4 reporter assay
SPECIFICATIONS
Specifications
IL-13
Mouse
Cellular assays
Sodium phosphate buffer, glycine, saccharose, stabilizing agents
< 5% (Invivofit™)
0.2 µm filtration (Invivofit™)
Negative (tested using EndotoxDetect™ assay)
Neutralization assay
Each lot is functionally tested using cellular assays.
CONTENTS
Contents
-
Product:Anti-mIL-13-mIgG1
-
Cat code:mil13-mab9-02
-
Quantity:200 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Interleukin 13 (IL-13) is a pleiotropic cytokine that plays an important role in inflammation, fibrosis, allergic diseases and cancer. It is mainly produced by activated T cells and regulates several subtypes of T helper (Th) cells by affecting their transformation, including Th1, Th2, and Th17 cells. Previous studies have revealed that IL-13 is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and type 1 diabetes (T1D) [1].
IL-13 also exerts its anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines, such as TNF‑α. The biological functions of IL-13 overlap with those of IL-4. In fact, both IL-4 and IL-13 can bind to the same receptor complex, IL-13 receptor (IL-13R), which is composed of two subunits IL-4Rα and IL-13Rα1 [2]. The binding of IL-4 or IL-13 to IL-13R instigates a signaling cascade involving the activation of receptor-associated Janus kinases (JAK1 and Tyk2) and the nuclear translocation of STAT6 (Signal Transducer and Activator of Transcription 6). The nuclear translocation of STAT6 ultimately leads to the induction of gene expression by IL-13 [3].
References:
1. Mao YM, et al., 2019. Interleukin-13: A promising therapeutic target for autoimmune disease. Cytokine Growth Factor Rev.;45:9-23.
2. David M. et al., 2003. Functional characterization of IL-13 receptor a2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression. Oncogene 22, 3386-94.
3. Dickensheets H.L. et al., 1999. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. PNAS. 96(19):10800-5.
DOCUMENTS
Documents
Technical Data Sheet
Safety Data Sheet
Validation Data Sheet
Certificate of analysis
Need a CoA ?